Dr.Reddy's Laboratories Ltd (REDY.NS)
28 Feb 2015
MUMBAI, Feb 2 - Indian shares fell on Monday, continuing their retreat from record highs hit last week as blue-chips including Dr.Reddy's Laboratories extended falls after disappointing earnings, while caution prevailed a day before the central bank's policy review.
** Delay in monetisation of key drugs such as Nexium and Copaxone, which implies low-teen FY16 EPS growth - Credit Suisse
** Dr.Reddy's Laboratories shares fall 1.2 pct ** Canadian importers agree to quarantine products from Dr.Reddy's Srikakulam plant and Ipca Laboratories' Pithampur facility, Health Canada says (http://bit.ly/1HyUTK4) ** Quarantine request due to data integrity concerns, Canadian drug regulator adds ** Continued concerns that sales in Russia may be impacted due to brewing financial crisis in the region also weigh (Reuters Messaging: email@example.com)
Shares of India's Dr Reddy's Laboratories gain 0.9 percent.
* Shares of India's Dr Reddy's Laboratories gain 0.9 percent. * Morgan Stanley upgrades the stock to "overweight" from "equal-weight"; raises price target to 3,875 rupees from 3,049 rupees. * Says drugmaker's U.S. pipeline outlook has strengthened and valuations appears to be reasonable. * "We expect a better outlook for FY16 and FY17 as underlined by improving India, and US businesses," it said. (firstname.lastname@example.org/indulal.p.thomsonreuters.com@reut ers.net)